HyeonJoo Cheon

HyeonJoo Cheon

HyeonJoo Cheon

Position Title

 Assistant Professor

Office Location

Karmanos Cancer Institute
Hudson-Webber Cancer Research Center - 640.1
4100 John R.
Detroit, MI 48201


Mailing Address

Karmanos Cancer Institute
4100 John R., HW06AO
Detroit, MI 48201



Office Phone


Education Training

(2004) Ph.D. in Biomedical Technology, Korea University, School of Life Sciences and Biotechnology, Seoul, South Korea.
(1996) M.S. in Molecular Biology, Yonsei University, Department of Biology, Seoul, South Korea
(1993) B.S. in Biology, Yonsei University, Department of Biology, Seoul, South Korea

Postgraduate Training
(2009) Cleveland Clinic, Lerner Research Institute, Department of Molecular Genetics, Cleveland, OH


Major Professional Societies

International Cytokine & Interferon Society (ICIS)
American Association for Cancer Research (AACR)


Philips RL, Wang Y, Cheon H, Kanno Y, Gadina M, Sartorelli V, Horvath CM, Darnell JE Jr, Stark GR, O'Shea JJ. The JAK-STAT pathway at 30: Much learned, much more to do.. Cell. 10/13/2022;185(21):3857-3876. PubMed PMID: 36240739.

Cheon H, Wang Y, Wightman SM, Jackson MW, Stark GR. How cancer cells make and respond to interferon-I.. Trends in cancer. 10/07/2022. PubMed PMID: 36216730.

Cheon H, Holvey-Bates EG, McGrail DJ, Stark GR. PD-L1 sustains chronic, cancer cell-intrinsic responses to type I interferon, enhancing resistance to DNA damage. Proceedings of the National Academy of Sciences of the United States of America. 11/23/2021;118(47). PubMed PMID: 34799452.

Kondratova AA, Cheon H~, Dong B, Holvey-Bates EG, Hasipek M, Taran I, Gaughan C, Jha BK, Silverman RH, Stark GR. Suppressing PARylation by 2',5'-oligoadenylate synthetase 1 inhibits DNA damage-induced cell death. The EMBO journal. 06/02/2020;39(11):e101573. PubMed PMID: 32323871.

Doherty MR, Parvani JG, Tamagno I, Junk DJ, Bryson BL, Cheon HJ, Stark GR, Jackson MW. The opposing effects of interferon-beta and oncostatin-M as regulators of cancer stem cell plasticity in triple-negative breast cancer. Breast cancer research : BCR. 04/29/2019;21(1):54. PubMed PMID: 31036052.

Doherty MR, Cheon H, Junk DJ, Vinayak S, Varadan V, Telli ML, Ford JM, Stark GR, Jackson MW. Interferon-beta represses cancer stem cell properties in triple-negative breast cancer. Proceedings of the National Academy of Sciences of the United States of America. 12/26/2017;114(52):13792-13797. PubMed PMID: 29229854.

Majoros A, Platanitis E, Szappanos D, Cheon H, Vogl C, Shukla P, Stark GR, Sexl V, Schreiber R, Schindler C, Müller M, Decker T. Response to interferons and antibacterial innate immunity in the absence of tyrosine-phosphorylated STAT1. EMBO reports. 03/01/2016;17(3):367-82. PubMed PMID: 26882544.

Sung PS, Cheon H, Cho CH, Hong SH, Park DY, Seo HI, Park SH, Yoon SK, Stark GR, Shin EC. Roles of unphosphorylated ISGF3 in HCV infection and interferon responsiveness. Proceedings of the National Academy of Sciences of the United States of America. 08/18/2015;112(33):10443-8. PubMed PMID: 26216956.

Wienerroither S, Shukla P, Farlik M, Majoros A, Stych B, Vogl C, Cheon H, Stark GR, Strobl B, Müller M, Decker T. Cooperative Transcriptional Activation of Antimicrobial Genes by STAT and NF-κB Pathways by Concerted Recruitment of the Mediator Complex. Cell reports. 07/14/2015;12(2):300-12. PubMed PMID: 26146080.

Kolosenko I, Fryknäs M, Forsberg S, Johnsson P, Cheon H, Holvey-Bates EG, Edsbäcker E, Pellegrini P, Rassoolzadeh H, Brnjic S, Larsson R, Stark GR, Grandér D, Linder S, Tamm KP, De Milito A. Cell crowding induces interferon regulatory factor 9, which confers resistance to chemotherapeutic drugs. International journal of cancer. 02/15/2015;136(4):E51-61. PubMed PMID: 25156627.


Faculty Status

Basic Science

← Return to listing